When the editors of Arthritis Research & Th erapy asked me to coordinate a review series on adult immunodefi ciency, I voluntarily agreed and suggested 10 topics. Th e editors selected six with the greatest importance for rheumatologists. Th e authors of the six articles all come from research groups with outstanding track-records in their respective fi elds.
Why present adult-onset immunodefi ciency to a readership of rheumatologists? Th e answer is simple. First, immunodefi ciency is a booming fi eld of translational immunology that should not be ignored by the rheumatologist. Second, there are increasing numbers of patients with symptoms of immunodefi ciency being seen in rheumatology clinics. Rheumatologists are often confronted with patients suff ering from either systemic autoimmune diseases plus drug-induced increased suscep tibility to infections or with alarming symptoms or with unusual laboratory values all indicative of a primary dysfunction of the immune system. Alarming symptoms include recurrent bouts of fever, frequent and prolonged infections, unusual pathogens, hepatosplenomegaly, lymph adenopathy, recurrent mucocutaneous candidiasis, spontaneous bone fractures, lung abscesses and noncaseating granulomas. Typical laboratory fi ndings are leukopenia, lymphopenia, low CD4 counts, myelo dysplasia, autoimmune hemolytic anemia and thrombo cytopenia as well as low concentrations of serum immunoglobulins or high IgE or IgM serum levels.
Who is best suited to take care of these patients in our current medical systems -the general physician, the hematologist, the infectious disease expert, the clinical immunologist or the rheumatologist? My honest view is that modern rheumatology, with its intricate links to clinical immunology, is the medical discipline best prepared to follow these patients and organize a close consultation platform with other disciplines, notably hematology, infectious disease and pathology. Along these lines, rheumatologists, clinical immunologists, pediatricians, infectious disease experts and pathologists have recently founded a unique Center of Chronic Immunodefi ciency at the Freiburg University Medical Center in Germany. Th e Center covers a hitherto unmet need for expert diagnosis and treatment of immunodysregulatory and immuno defi ciency syndromes both in children and adults. Up to 10 new patients are seen every week. Many of these patients suff er from an established or a novel genetic defect. About 40% of the patients with proven monogenic immunodefi ciency syndromes also present with symptoms of systemic or localized autoimmunity. Rheumatologists should therefore become acquainted with the notion that systemic collagen-vascular disease and infl ammatory joint diseases are likely to belong to a spectrum of immunodysregulatory syndromes that com prise, in addition to autoimmunity and immuno defi ciency, nonmalignant lymphoproliferation and granu lo matous disease.
Th e clinical phenotype in these patients can be dominated by either autoimmunity or immunodefi ciency, depending on the mixture of polymorphisms or mutations and deletions in genes involved in the innate and adaptive immune response. Environmental, metabolic and epigenetic factors can add to the complexity of the underlying pathophysiology. A prominent example of this situation relates to ICOS defi ciency (inducible T-cell costimulator; CD278): a deletion mutation described in Europe exhibits the classical phenotype of common variable immunodefi ciency [1] , whereas a diff erent mutation in the same gene reported in Japan associates more with autoimmunity symptoms [2] . Similar fi ndings have been observed for mutations in the gene coding for the Wiskott-Aldrich syndrome protein: depending on the site of the mutation, either X-linked thrombocytopenia or the full-blown Wiskott-Aldrich syndrome phenotype can occur [3] . Th e list of such genotype-phenotype relationships oscillating between immunodefi ciency and autoimmunity is long.
In the present review series on adult immunodefi ciency, six topics of particular interest to pediatric and adult rheumatology have been selected.
A problem encountered quite often in rheumatology is a low CD4 count with or without opportunistic infections. Th e diff erential diagnosis is demanding: HIV infection but also systemic lupus erythematosus, Sjögren's syndrome, primary immunodefi ciencies, hemophagocytic syndromes, idiopathic CD4 lymphopenia and druginduced eff ects may all hide behind this scenario. Zonios and colleagues have critically reviewed this challenging topic [4] .
Remarkable scientifi c progress has been made on hyper-IgM syndromes and hypogammaglobulinemia/common variable immunodefi ciency. Durandy and Kracker [5] and Salzer and colleagues [6] have expertly reviewed each fi eld respectively and pointed out their relevance for rheumatology.
Similarly, macrophage activation syndromes that lead to life-threatening hemophagocytic lymphohistiocytosis are of great interest for rheumatologists. Th ese conditions can affl ict children and adults as familial lympho histiocytic hemophagocytosis due to typical mutations in genes controlling vesicle transport in cytotoxic lymphocytes, or they can occur idiopathically in the context of childhood or adult-onset Still's disease, persistent viral infections (Epstein-Barr virus, cytomegalovirus) or drug hypersensitivity. Th ese patients require a fast and competent diagnosis and an early identifi cation of individuals who need to be directed towards allogeneic stem cell transplantation -the only curative procedure available. Ehl's group has reviewed the new developments in this fascinating fi eld [7] .
Finally, rheumatologists will profi t from an increased awareness of two important areas of recent discoveries: fi rst, a series of gene defects leading to deregulated IL-17 responses in chronic mucocutaneous candidiasis reviewed by Gaff en's group [8] ; and, second, the crucial importance of mutations in the signal transduction molecules STAT3 and DOCK8 in hyper-IgE syndrome reviewed by Yong and colleagues [9] .
Th e editors' decision to off er this review series to a rheumatology readership is both daring and visionary: daring because it will challenge rheumatologists to engage in new clinical areas, and visionary because it aims at directing rheumatology deeper into clinical immunology, immunodysregulation and novel strategies of targeted therapies. Th e authors of this issue are convinced that the chosen direction is an important asset for modern rheumatology.
Abbreviations DOCK, dedicator of cytokinesis; ICOS, inducible T-cell costimulator (CD278); IL, interleukin; STAT, signal transducer and activator of transcription.
